• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

SPR Therapeutics Names Dr. Peter Staats as Chief Medical Advisor

January 15, 2019

Peter Staats, MD, MBA, will advise on the continued advancement of the SPRINT Peripheral Nerve Stimulation platform technology for pain management

Peter Staats, MD, MBACLEVELAND, Jan. 15, 2019 (GLOBE NEWSWIRE) — SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced that Peter Staats, MD, MBA, has been named Chief Medical Advisor. Dr. Staats brings nearly three decades of diverse entrepreneurial experience in pain management and neuromodulation technology to this key role at SPR.

Dr. Staats joins SPR Therapeutics at an exciting time for the company, as adoption of the SPRINT® PNS System is growing rapidly among leading pain management specialists following its recent FDA clearance.  Dr. Staats will provide advice and guidance to SPR in the areas of patient selection, clinical trial design, physician training, product enhancements, and reimbursement strategies, among others.

“We are thrilled and honored to have Dr. Staats join SPR as Chief Medical Advisor. His extensive knowledge and experience as a treating physician, entrepreneur and advisor to HHS, will be tremendous assets for our company as we expand commercialization of our proven peripheral nerve stimulation (PNS) therapy to patients and physicians,” said Maria Bennett, Founder, President and CEO of SPR Therapeutics. “We look forward to working even more closely with Dr. Staats as we continue to advance our SPRINT PNS System, addressing the critical need for less invasive, earlier stage non-opioid pain management therapies.”

“I’m delighted to be collaborating with SPR Therapeutics and helping the company expand the adoption of its pain management therapy in those patients most likely to benefit from their SPRINT percutaneous PNS System,” said Dr. Staats.  “I’m encouraged by the results achieved to date and by the potential for this device to provide a much-needed neuromodulation option that is reasonable to use early in the care continuum.”

Dr. Staats has served as the President of several societies, including American Society of Interventional Pain Physicians (ASIPP), North American Neuromodulation Society (NANS), New Jersey Society of Interventional Pain Physicians and the Southern Pain Society, and has co-edited or authored 10 textbooks on pain medicine and written nearly three hundred articles, book chapters and abstracts on the diagnosis and management of complex pain problems, appearing in publications such as JAMA, Lancet, and Pain Medicine. Following his role at Johns Hopkins University he was a founding partner in Premier Pain Centers in New Jersey, which recently merged with National Spine and Pain Centers.

About SPRINT® PNS System
The SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device that is FDA-cleared for both chronic and acute pain, including post-operative and post-traumatic pain. The SPRINT PNS System leads are placed by a physician during an outpatient procedure without surgery, incisions, tissue destruction or anesthesia, and are connected to a wearable stimulator that delivers stimulation for up to 60 days of therapy. The lead is then removed. In multiple studies, the SPRINT system has demonstrated significant and sustained pain relief post-60-day treatment. Physicians have used the SPRINT system to treat post-amputation pain, shoulder pain, lower back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement (partial listing). For additional information regarding safety and efficacy visit sprtherapeutic.wpengine.com. 

About SPR Therapeutics, Inc.
SPR Therapeutics, Inc. is a privately-held medical device company headquartered in Cleveland, Ohio, focused on developing, manufacturing and commercializing non-opioid, minimally invasive, treatment options that reduce pain and improve quality of life. The company’s SPRINT technology is the only percutaneous Peripheral Nerve Stimulation (PNS) System FDA-cleared to treat both chronic and acute pain. More information can be found at: sprtherapeutic.wpengine.com.

SPR Contact:
Mark Stultz
Senior Vice President
mstultz@sprtherapeutics.com
612-770-0390

Media Contact:
Helen Shik
Shik Communications LLC
ShikPR@sprtherapeutics.com
617-510-4373

GlobeNewswire Press Release
View this press release on GlobeNewswire’s site.

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: News
Previous Post:SPR Therapeutics Announces First Use of SPRINT endura Peripheral Nerve Stimulation System to treat Complex Regional Pain Syndrome
Next Post:NANS 2019

Sidebar

Archives

Recent News

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo